Page 91 - ITPS-7-4

INNOSC Theranostics and
Pharmacological Sciences Digital therapeutics for obesity management

Personalized medicine is another promising avenue, Acknowledgments
with genetic insights allowing for highly individualized
treatment strategies. The use of big data and advanced None.
analytics will enable PDTs to deliver more tailored Funding
interventions, considering each individual’s unique
behavioral, emotional, and physiological profile. Big data is None.
helpful for training of health models, which can be further
leveraged to bring DTx solutions for chronic diseases into Conflict of interest
real life. 38 The authors declare that they have no competing interests.

Integrating PDTs into standard healthcare practices
will be crucial for their widespread adoption. This will Author contributions
require strong collaboration between tech companies and Conceptualization: Shubhima Grover
healthcare providers to ensure that PDTs are effectively Visualization: Hara Prasad Mishra
integrated into patient care plans. In addition, the future Writing–original draft: Hara Prasad Mishra
regulatory landscape will need to evolve, with advocacy Writing–review & editing: All authors
for standardized regulations across regions to ensure the
safety, efficacy, and accessibility of PDTs. Ethics approval and consent to participate
Overall, the future of PDTs in obesity management Not applicable.
holds great promise, with technological innovations
and personalized approaches driving more effective and Consent for publication
engaging solutions. This progress will ultimately empower Not applicable.
the affected individuals to take a more proactive attitude in
managing obesity and improve the overall health outcomes. Availability of data
6. Conclusion Not applicable.
PDTs have revolutionized the approach to obesity References
management by integrating advanced digital technologies 1. Bray GA, Frühbeck G, Ryan DH, Wilding JPH. Management
with behavioral medicine. These innovative solutions, of obesity. Lancet. 2016;387(10031):1947-1956.
like WellDoc’s BlueStar , provide personalized health
®
guidance and real-time support, significantly enhancing doi: 10.1016/S0140-6736(16)00271-3
patient engagement and adherence. Clinical studies have 2. Boutari C, Mantzoros CS. A 2022 update on the
validated the effectiveness of PDTs, underscoring their epidemiology of obesity and a call to action: As its twin
potential in improving health outcomes for individuals COVID-19 pandemic appears to be receding, the obesity and
with obesity. dysmetabolism pandemic continues to rage on. Metabolism.
2022;133:155217.
Despite their promise, PDTs face challenges such as
regulatory hurdles, user engagement issues, data privacy doi: 10.1016/j.metabol.2022.155217
concerns, and accessibility barriers. Addressing these 3. Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification
challenges through improved regulatory frameworks, approaches for the treatment of obesity in adults. Am
user interface enhancements, robust data security Psychol. 2020;75(2):235-251.
measures, and efforts to bridge the digital divide is doi: 10.1037/amp0000517
essential for realizing the full potential of these digital
interventions. 4. Digital Therapeutics Alliance. A New Category of Medicine.
Arlington: Digital Therapeutics Alliance; 2020. Available
In future, the continued advancement of technology, from: https://dtxalliance.org [Last accessed on 2021 Feb 23].
including AI, wearable devices, and personalized
medicine, will further drive the impact of PDTs in obesity 5. Patel NA, Butte AJ. Characteristics and challenges of the
clinical pipeline of digital therapeutics. NPJ Digit Med.
management. Integrating these tools within healthcare 2020;3:159.
systems and establishing standardized regulatory policies
will be crucial for scaling their benefits. As PDTs evolve, doi: 10.1038/s41746-020-00370-8
they offer the promise of more effective obesity management 6. Quinn CC, Shardell MD, Terrin ML, Barr EA, Ballew SH,
and empower individuals to take proactive control of their Gruber-Baldini AL. Cluster-randomized trial of a mobile
health, adapting to the ever-evolving digital healthcare. phone personalized behavioral intervention for blood

Volume 7 Issue 4 (2024) 8 doi: 10.36922/itps.4042